Octreotide therapy for recurrent refractory hypoglycemia due to sulfonylurea in diabetes-related kidney failure

Endocrine Practice

Volumn 13, Issue 4, 2007, Pages 417-423

  Gonzalez, Rita R ^a   Zweig, Susan ^a   Rao, Jyoti ^a   Block, Romy ^a   Greene, Loren W ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GASTROINTESTINAL AGENT; GLIBENCLAMIDE; OCTREOTIDE;

AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DIABETIC NEPHROPATHY; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RECURRENT DISEASE;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GASTROINTESTINAL AGENTS; GLYBURIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE; MALE; OCTREOTIDE; RECURRENCE;

EID: 34548438883     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.4.417     Document Type: Review

References (37)

1. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am. 1989;18:163-183.
2. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001: 1701-1705.
3. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with endstage renal disease. Am J Kidney Dis. 2000;35:500-505.
4. Graudins A, Kinden CH, Ferm RP. Diagnosis and treatment of sulfonylurea-induced hyperinsulinemic hypoglycemia. Am J Emerg Med. 1996;14:95-96.
5. Krentz AJ, Boyle PJ, Justice KM, Wright AD, Schade DS. Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide. Diabetes Care. 1993;1:184-186.
6. Crawford BA, Perera C. Octreotide treatment for sulfonylurea-induced hypoglycemia. Med J Aust. 2004;180: 540-541.
7. Nzerue CM, Thomas J, Volgy J, Edeki T. Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure. Int J Artif Organs. 2003;26:86-89.
8. Braatvedt GD. Octreotide for the treatment of sulfonylurea induced hypoglycaemia in type 2 diabetes. N Z Med J. 1997;110:189-190.
9. McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2000;36:133-138.
10. Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab. 1993;76:752-756.
11. Green RS, Palatnick W. Effectiveness of octreotide in a case of refractory sulfonylurea-induced hypoglycemia. J Emerg Med. 2003;25:283-287.
12. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.
13. Haviv YS, Sharkia M, Safadi R. Hypoglycemia in patients with renal failure. Ren Fail. 2000;22:219-223.
14. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am. 1989;18:103-121.
15. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382-391.
16. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724-733.
17. ter Braak EW, Appelman AM, van der Tweel I, Erkelens DW, van Haeften TW. The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. Diabetes Care. 2002;25:107-112.
18. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 2003;26:1852-1855.
19. Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia, PA: Saunders, 2003: 1427-1483.
20. Gerich JE. Oral hypoglycemic agents [erratum in N Engl J Med. 1990;322:71]. N Engl J Med. 1989;321:1231-1245.
21. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51(Suppl 3):S368-S376.
22. Spiller HA. Management of sulfonylurea ingestions. Pediatr Emerg Care. 1999;15:227-230.
23. Harrigan RA, Nathan MS, Beatie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med. 2001;38:68-78.
24. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care. 1994;17:1026-1030.
25. Holst JJ. Glucagon, glucagon-like peptide-1 and their receptors: an introduction. Acta Physiol Scand. 1996; 157:309-315.
26. Oakley NW, Harrigan P, Kissebah AH, Kissin EA, Adams PW. Factors affecting insulin response to glucagon in man. Metabolism. 1972;21:1001-1007.
27. Palatnick W, Meatherall RC, Tenenbein M. Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med. 1991;151:1859-1862.
28. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334:246-254.
29. Mitra SW, Mezey E, Hunyady B, et al. Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology. 1999;140:3790-3796.
30. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005;80:502-506.
31. Rossowski WJ, Coy DH. Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochem Biophys Res Commun. 1994;205:341-346.
32. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198.
33. Lamberts SW, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 1985;60:1161-1165.
34. Brunicardi FC, Atiya A, Moldovan S, et al. Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas. Pancreas. 2003;27:e84-e89.
35. Hearn PR, Ahmed M, Woodhouse NJ. The use of SMS 201-995 (somatostatin analogue) in insulinomas: additional case report and literature review. Horm Res. 1988;29:211-213.
36. Sari R, Altunbas H, Ozdogan M, Gurer EI, Karayalcin U. Severe and prolonged hypoglycemia triggered by longacting octreotide in a patient with malignant mesenchymal tumor: case report. J Chemother. 2003;15:85-88.
37. Lheureux PE, Zahir S, Penaloza A, Gris M. Bench-to bedside review: antidotal treatment of sulfonylurea-induced hypoglycemia with octreotide. Crit Care. 2005; 9:543-549.